Efficacy and safety of [11C]MePro as a novel PET probe in patients with pancreatic cancer

Takahashi Miwako0 个研究点目标入组 20 人开始时间: 2023年9月7日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Subjects who are 18 years of age or older at the time of consent acquisition
•2. Subjects who have been confirmed to have pancreatic cancer by histopathological or clinical examination
•3. Subjects who have performed or are scheduled to perform [18F]FDG PET/CT by insurance within 30 days before or after the date of obtaining [11C] MePro PET/CT imaging, if [18F]FDG PET/CT imaging information is to be used
•4. Subjects whose Performance Status (ECOG PS) is 0 or 1
•5. Subjects who provide written informed consent

•1. Subjects who have severe or progressive complications or subjects who have a history of these complications and are judged by the investigator or co-investigator to be unsuitable for this study
•2. Subjects who have obvious abnormalities in physical and laboratory examinations (blood test and urinalysis) after obtaining the informed consent
•3. Subjects with drug addiction or alcohol addiction
•4. Subjects with mental illness or psychiatric symptoms who are judged to have difficulty in participating in this study
•5. Subjects who are unable or restricted from the tests specified in the research plan
•6. Subjects who are claustrophobic
•7. Subjects who are considered to be inappropriate to participate in this study by the investigator or co-investigator

发起方

Takahashi Miwako